Mutation in the ATP-binding pocket of the ABL kinase domain in an STI571-resistant BCR/ABL-positive cell line1

Clara Ricci, Barbara Scappini, Vladimir Divoky, Simona Gatto, Francesco Onida, Srdan Verstovsek, Hagop M. Kantarjian, Miloslav Beran

Research output: Contribution to journalArticle

69 Citations (Scopus)

Abstract

The major mechanism of action of STI571 is a competitive interference with the ATP-binding site of the Bcr/Abl tyrosine kinase. In the BCR/ABL-positive cell line KBM5, we studied cellular events associated with the in vitro acquisition of resistance to STI571. The emergence of the STI571 -resistant phenotype was accompanied by only a marginal increase in the number of copies of the BCR/ABL gene and its level of expression. The activity of the Bcr/Abl kinase (level of autophosphorylation) in resistant cells was, however, incompletely inhibited by STI571, and the acquisition of the high degree of resistance was associated with a single-point mutation leading to a substitution of a threonine-to-isoleucine at position 315 of Abl. In the resistant KBM5-STI571R1.0 cells. 20% of the BCR/ABL transcripts and 10% of BCR/ABL gene copies on the DNA level were mutated. The mutation was present in all 10 STI571-resistant clones derived from low density clonogenic assay, confirming its presence in all colony-forming cells but only in a fraction of the BCR/ABL gene copies in each cell. The contribution of this mutation to STI571-resistant phenotype remains unknown. Preliminary data showing partial reversibility of resistance in these cells suggest that resistance may be multifactorial. No other mutations were identified in the kinase domain of the BCR/ABL gene.

Original languageEnglish
Pages (from-to)5995-5998
Number of pages4
JournalCancer Research
Volume62
Issue number21
Publication statusPublished - Nov 1 2002

Fingerprint

Phosphotransferases
Adenosine Triphosphate
Mutation
Genes
bcr-abl Fusion Proteins
Phenotype
Isoleucine
Threonine
Point Mutation
Imatinib Mesylate
Clone Cells
Binding Sites
Cell Line
DNA

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Ricci, C., Scappini, B., Divoky, V., Gatto, S., Onida, F., Verstovsek, S., ... Beran, M. (2002). Mutation in the ATP-binding pocket of the ABL kinase domain in an STI571-resistant BCR/ABL-positive cell line1. Cancer Research, 62(21), 5995-5998.

Mutation in the ATP-binding pocket of the ABL kinase domain in an STI571-resistant BCR/ABL-positive cell line1. / Ricci, Clara; Scappini, Barbara; Divoky, Vladimir; Gatto, Simona; Onida, Francesco; Verstovsek, Srdan; Kantarjian, Hagop M.; Beran, Miloslav.

In: Cancer Research, Vol. 62, No. 21, 01.11.2002, p. 5995-5998.

Research output: Contribution to journalArticle

Ricci, C, Scappini, B, Divoky, V, Gatto, S, Onida, F, Verstovsek, S, Kantarjian, HM & Beran, M 2002, 'Mutation in the ATP-binding pocket of the ABL kinase domain in an STI571-resistant BCR/ABL-positive cell line1', Cancer Research, vol. 62, no. 21, pp. 5995-5998.
Ricci C, Scappini B, Divoky V, Gatto S, Onida F, Verstovsek S et al. Mutation in the ATP-binding pocket of the ABL kinase domain in an STI571-resistant BCR/ABL-positive cell line1. Cancer Research. 2002 Nov 1;62(21):5995-5998.
Ricci, Clara ; Scappini, Barbara ; Divoky, Vladimir ; Gatto, Simona ; Onida, Francesco ; Verstovsek, Srdan ; Kantarjian, Hagop M. ; Beran, Miloslav. / Mutation in the ATP-binding pocket of the ABL kinase domain in an STI571-resistant BCR/ABL-positive cell line1. In: Cancer Research. 2002 ; Vol. 62, No. 21. pp. 5995-5998.
@article{247264c7e32f4142a7672b879975f7cc,
title = "Mutation in the ATP-binding pocket of the ABL kinase domain in an STI571-resistant BCR/ABL-positive cell line1",
abstract = "The major mechanism of action of STI571 is a competitive interference with the ATP-binding site of the Bcr/Abl tyrosine kinase. In the BCR/ABL-positive cell line KBM5, we studied cellular events associated with the in vitro acquisition of resistance to STI571. The emergence of the STI571 -resistant phenotype was accompanied by only a marginal increase in the number of copies of the BCR/ABL gene and its level of expression. The activity of the Bcr/Abl kinase (level of autophosphorylation) in resistant cells was, however, incompletely inhibited by STI571, and the acquisition of the high degree of resistance was associated with a single-point mutation leading to a substitution of a threonine-to-isoleucine at position 315 of Abl. In the resistant KBM5-STI571R1.0 cells. 20{\%} of the BCR/ABL transcripts and 10{\%} of BCR/ABL gene copies on the DNA level were mutated. The mutation was present in all 10 STI571-resistant clones derived from low density clonogenic assay, confirming its presence in all colony-forming cells but only in a fraction of the BCR/ABL gene copies in each cell. The contribution of this mutation to STI571-resistant phenotype remains unknown. Preliminary data showing partial reversibility of resistance in these cells suggest that resistance may be multifactorial. No other mutations were identified in the kinase domain of the BCR/ABL gene.",
author = "Clara Ricci and Barbara Scappini and Vladimir Divoky and Simona Gatto and Francesco Onida and Srdan Verstovsek and Kantarjian, {Hagop M.} and Miloslav Beran",
year = "2002",
month = "11",
day = "1",
language = "English",
volume = "62",
pages = "5995--5998",
journal = "Journal of Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "21",

}

TY - JOUR

T1 - Mutation in the ATP-binding pocket of the ABL kinase domain in an STI571-resistant BCR/ABL-positive cell line1

AU - Ricci, Clara

AU - Scappini, Barbara

AU - Divoky, Vladimir

AU - Gatto, Simona

AU - Onida, Francesco

AU - Verstovsek, Srdan

AU - Kantarjian, Hagop M.

AU - Beran, Miloslav

PY - 2002/11/1

Y1 - 2002/11/1

N2 - The major mechanism of action of STI571 is a competitive interference with the ATP-binding site of the Bcr/Abl tyrosine kinase. In the BCR/ABL-positive cell line KBM5, we studied cellular events associated with the in vitro acquisition of resistance to STI571. The emergence of the STI571 -resistant phenotype was accompanied by only a marginal increase in the number of copies of the BCR/ABL gene and its level of expression. The activity of the Bcr/Abl kinase (level of autophosphorylation) in resistant cells was, however, incompletely inhibited by STI571, and the acquisition of the high degree of resistance was associated with a single-point mutation leading to a substitution of a threonine-to-isoleucine at position 315 of Abl. In the resistant KBM5-STI571R1.0 cells. 20% of the BCR/ABL transcripts and 10% of BCR/ABL gene copies on the DNA level were mutated. The mutation was present in all 10 STI571-resistant clones derived from low density clonogenic assay, confirming its presence in all colony-forming cells but only in a fraction of the BCR/ABL gene copies in each cell. The contribution of this mutation to STI571-resistant phenotype remains unknown. Preliminary data showing partial reversibility of resistance in these cells suggest that resistance may be multifactorial. No other mutations were identified in the kinase domain of the BCR/ABL gene.

AB - The major mechanism of action of STI571 is a competitive interference with the ATP-binding site of the Bcr/Abl tyrosine kinase. In the BCR/ABL-positive cell line KBM5, we studied cellular events associated with the in vitro acquisition of resistance to STI571. The emergence of the STI571 -resistant phenotype was accompanied by only a marginal increase in the number of copies of the BCR/ABL gene and its level of expression. The activity of the Bcr/Abl kinase (level of autophosphorylation) in resistant cells was, however, incompletely inhibited by STI571, and the acquisition of the high degree of resistance was associated with a single-point mutation leading to a substitution of a threonine-to-isoleucine at position 315 of Abl. In the resistant KBM5-STI571R1.0 cells. 20% of the BCR/ABL transcripts and 10% of BCR/ABL gene copies on the DNA level were mutated. The mutation was present in all 10 STI571-resistant clones derived from low density clonogenic assay, confirming its presence in all colony-forming cells but only in a fraction of the BCR/ABL gene copies in each cell. The contribution of this mutation to STI571-resistant phenotype remains unknown. Preliminary data showing partial reversibility of resistance in these cells suggest that resistance may be multifactorial. No other mutations were identified in the kinase domain of the BCR/ABL gene.

UR - http://www.scopus.com/inward/record.url?scp=0036827727&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036827727&partnerID=8YFLogxK

M3 - Article

VL - 62

SP - 5995

EP - 5998

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0008-5472

IS - 21

ER -